AstraZeneca opens expanded Texas manufacturing facility

AstraZeneca (NASDAQ: AZN) opened its expanded manufacturing facility in Coppell, Texas, following a $445 million investment to double production of Lokelma, a medication used to treat hyperkalemia.

The expansion adds a 9,000 square foot building with two manufacturing lines, enhanced laboratory testing capabilities, warehousing space, and additional administrative areas. The facility serves as the sole global manufacturing site for Lokelma, supplying more than 50 countries worldwide.

The Coppell facility employs more than 250 people and has operated for 10 years. The expansion forms part of AstraZeneca's announced $50 billion investment in US research and development and manufacturing over five years, which was disclosed in July 2025.

"Our manufacturing facility in Coppell serves as both a critical pillar in global healthcare and has played an important role in supporting the local workforce over the past 10 years," said Jim Fox, Senior Vice President, Americas Supply Operations at AstraZeneca.

The company recently broke ground on another manufacturing facility in Albemarle County, Virginia, as part of the same investment program. At the Coppell facility opening event, AstraZeneca's STEM education partner Learning Undefeated introduced an interactive mobile laboratory called Breakout Box: Manufacturing Mission, designed to expose students to manufacturing careers in areas including welding, data analytics, and robotics.

You May Also Be Interested In